Dermira reports data on underarm sweating treatment DRM04
Dermira presented data, including new disease-related quality of life data, from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis at the European Academy of Dermatology and Venereology Congress. In June, positive topline results from the Phase 3 ATMOS-1 and ATMOS-2 pivotal trials evaluating the safety and efficacy of DRM04, a topical anticholinergic product candidate, compared to vehicle were reported showing significant improvements in patient-reported disease severity following four weeks of treatment. New findings presented at EADV found that patients treated with DRM04 reported significant improvements in their disease-related quality of life compared to patients who received vehicle only. DRM04 showed a mean improvement from baseline in the Dermatology Life Quality Index score compared to vehicle in both the ATMOS-1 -- decrease of 8.1 vs. 4.3 -- and ATMOS-2 -- decrease of 8.6 vs. 5.0 -- clinical trials, at week 4. Dermira said it intends to present additional patient quality of life data as measured by the Axillary Sweating Daily Diary in peer-reviewed forums.